Target intelligence / Profile preview

Desmocollin-1 (DSC1)

Target
DSC1
Molecular classification
Cadherin family protein, Desmocollin subfamily, Cell adhesion molecule, Transmembrane glycoprotein, Other
01

Overview

Desmocollin-1 (DSC1) is a calcium-dependent, transmembrane glycoprotein belonging to the cadherin superfamily, specifically the desmocollin subfamily[3][2][1]. It is a major constituent of desmosomes—specialized cell-cell junctions found primarily in epithelial tissues—where it mediates strong intercellular adhesion by forming adhesive heterodimers with desmogleins[4][1]. DSC1 is especially prominent in terminally differentiating keratinocytes of the upper epidermis and hair follicles, playing key roles in maintaining skin integrity and barrier function[1][3]. DSC1 is implicated in disease processes including the pathogenesis of autoimmune blistering disorders like IgA pemphigus (autoantibody target) and has been linked to metastatic progression in certain breast cancer subtypes: overexpression promotes tumor cell migration and invasion, and its downregulation reduces pro-metastatic pathways. Modulation of DSC1 (e.g., by parthenolide) can disrupt cell adhesion and related molecular networks, underlining its therapeutic target potential and associated safety considerations[2][3][1].

Other names
Desmocollin-1DSC1CDHF1DG2/DG3Cadherin family member 1Desmosomal glycoprotein 2/3desmocollin-1cadherin family member 1desmosomal glycoprotein 2/3
02

Mechanism of action

Modulation of DSC1 expression or protein-protein interactions affecting cell adhesion and signaling (parthenolide decreases DSC1 level and disrupts associated molecular pathways)

03

Biological functions

Cell-to-cell adhesionDesmosome assemblyMaintenance of epidermal barrierRegulation of keratinocyte differentiationPositive regulation of cellular adhesionMaintenance of hair follicle morphology
04

Disease associations

Cancer (notably breast cancer metastasis)Autoimmune disease (e.g., IgA pemphigus)Skin disorders (e.g., subcorneal pustular dermatosis)Other
05

Safety considerations

Loss or inhibition may compromise skin barrier integrity and hair follicle morphologyAutoantibody targeting can lead to life-threatening skin blistering diseases (pemphigus)May influence epithelial tumor invasiveness—therapeutic targeting may affect normal tissue stability
06

Interacting drugs

Parthenolide (NF-κB inhibitor, shown to decrease DSC1 protein levels in vitro)
07

Biomarkers

Elevated in metastatic and higher grade breast cancers (potential biomarker for cancer invasiveness/metastasis)Detected in skin biopsies for autoimmune blistering diseases (diagnostic autoantibody target in IgA pemphigus)

Beyond the preview

Go deeper on Desmocollin-1 (DSC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Desmocollin-1 (DSC1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call